CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

Vairy S, Lopes Garcia J, Teira P, Bittencourt H

Drug Design, Development and Therapy 2018, 12:3885-3898

Published Date: 12 November 2018